Dr. Reddy’s Laboratories-Q3 FY26 Earnings Call Note-Revenue edged up 4.4% year-over-year to ₹8,727 crore
Dr. Reddy’s Laboratories reported mixed Q3 FY26 results, with revenue rising 4.4% to ₹8,727 crore but profit dropping 14% to ₹1,210 crore due to Lenalidomide sales decline. Strong growth in India and emerging markets offset US challenges. The company remains optimistic about its pipeline and strategic focus despite near-term margin pressures.
You must be logged in to post a comment.